PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7609
- Registration Number
- NCT00205777
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Use of 852A in Metastatic Cutaneous Melanoma.
Phase 2
Completed
- Conditions
- MelanomaUnresectable Metatstatic Cutaneous Melanoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-10-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00189332
- Locations
- 🇫🇷
Hôpital Ste Marguerite,Service de Dermatologie, Marseilles, France
🇩🇪Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany
🇩🇪(DKFZ) an der Universitäts-Hautklinik Mannheim, Mannheim, Germany
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00195260
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1014
- Registration Number
- NCT00195403
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00195338
- Locations
- 🇱🇺
Pfizer Investigational Site, Luxembourg, Luxembourg
Donepezil in the Prevention of Post-Operative Cognitive Decline
Phase 4
Completed
- Conditions
- Postoperative ComplicationsDelirium
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00182845
- Locations
- 🇺🇸
University Hospital, Clarian Health Partners, Indianapolis, Indiana, United States
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Phase 4
Terminated
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00174239
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00174291
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00174187
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
Phase 3
Completed
- Conditions
- Fetal Growth Retardation
- Interventions
- Drug: Genotonorm (Somatropin)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT00174252
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy, France
© Copyright 2025. All Rights Reserved by MedPath